Macrophages drive atherosclerotic plaque progression and rupture, hence attenuating their 50 atherosclerosis-inducing properties holds promise for reducing coronary heart disease (CHD). 51 Recent studies in mouse models have demonstrated that Tribbles 1 (Trib1) regulates macrophage 52 phenotype and shows that Trib1 deficiency increases plasma cholesterol and triglyceride levels, 53 suggesting that reduced TRIB1 expression mediates the strong genetic association between the 54 TRIB1 locus and increased CHD risk in man. However, we report here that myeloid-specific 55 Trib1 (mTrib1) deficiency reduces early atheroma formation and that mTrib1 transgene 56 expression increases atherogenesis. Mechanistically, mTrib1 increased macrophage lipid 57 accumulation and the expression of a critical receptor (OLR1), promoting oxidized low density 58 lipoprotein uptake and the formation of lipid-laden foam cells. As TRIB1 and OLR1 RNA levels 59 were also strongly correlated in human macrophages, we suggest that a conserved, TRIB1-60 mediated mechanism drives foam cell formation in atherosclerotic plaque and that inhibiting 61 mTRIB1 could be used therapeutically to reduce CHD. 62 63 64 MAIN TEXT 65 66 67 102 disease (14-16) relates to loss of TRIB1 activity. 103 104
Introduction 68 69
Atherosclerosis, a progressive disease of arterial blood vessels and the main underlying cause of 70 stroke, myocardial infarction and cardiac death (1), is initiated by the conversion of plaque-71 macrophages to cholesterol-laden foam cells (2) in the arterial intima (3). In the early-stage 72 atherosclerotic plaque this transformation is induced by the uptake of both LDL-C and oxidized 73 (ox)LDL (2, 4), which may serve a beneficial purpose (3); but unrestrained, the crucial function of 74 plaque-macrophages in resolving local inflammation is compromised and the development of 75 unstable, advanced lesions ensues (3). Importantly, it has been shown that foamy macrophages are 76 not only less effective in clearing apoptotic cells (5) they are also more prone to apoptosis (6), 77 thus increasing secondary necrosis and the release of cellular components and lipids that 78 ultimately form the necrotic core of advanced plaques. As such, there have been investigations 79 into the identities of macrophage-specific proteins that induce lipid accumulation. Thus, myeloid-80 lipoprotein lipase (LPL), for example, has been shown to enhance the retention of LDL-C and 81 triglyceride-rich remnant particles within the artery wall (7) and induce foam cell formation (8) ; 82 while the scavenger receptor, oxidized low-density lipoprotein receptor 1 (OLR1) has been found 83 to internalize oxLDL (9), promoting not only lipid accumulation and growth but also the survival 84 of macrophage-foam cells (10) . Conversely, myeloid-ApoE expression has been shown to 85 promote HDL-mediated cholesterol efflux (11) and macrophage switching from a pro-86 inflammatory (M1) to an alternatively (M2) activated phenotype (12) . However, significant 87 advances in the development of CVD therapeutics await the identification of an apical 88 regulator(s) that acts in a coordinated manner on the multiple downstream processes governing 89 lipid accumulation, as well as atherogenicity of plaque-resident macrophages. Tribbles-1 has been detected in murine plaque-resident macrophages (13) and variants at the 92 TRIB1 locus have been associated with increased risk of hyperlipidemia and atherosclerotic 93 disease in multiple populations (14) (15) (16) ). However, no study had examined the macrophage-94 specific cellular processes dependent on mTrib1 expression and how these tally with the assumed 95 athero-protective properties of this pseudokinase. At the whole-body level, one study has shown 96 that Trib1 deficient mice have markedly reduced numbers of M2-like (F4/80 + MR + ) macrophages 97 in multiple organs, including adipose tissue (17) . As such, these studies strongly implicated that 98 loss of macrophage-Trib1 expression within the arterial wall would lead to excessive 99 atherosclerotic plaque inflammation and/or impair inflammation resolution and promote atheroma 100 formation. Moreover, in hepatocytes Trib1 suppresses VLDL production and de novo lipogenesis 101 (16), indicating that the association between variants at the TRIB1 locus and atherosclerotic 116 Immunostaining of a human coronary atheroma detected Tribbles 1 in the arterial wall, including 117 in macrophages (Fig 1A) . We therefore examined the impact of macrophage Tribbles 1 118 expression on atherogenesis by creating mice expressing low, WT and elevated levels of myeloid 119 Trib1 as outlined in Fig 1 B -F . Although previous studies have demonstrated that global Trib1 120 KO significantly increases perinatal lethality (17) Trib1-floxed mice and myeloid-specific Trib1 121 knock-out (Trib1 mKO ) mice were fully viable and bred normally (Fig S1 A-D) . Trib1 transgenic (overexpressing, Trib1 mTg ) mice were also fully viable and bred normally. 123 mTrib1 RNA levels were substantially lower in Trib1 mKO than in floxed WT littermates, as judged 124 by RT-qPCR assays performed on bone marrow-derived macrophages (BMDMs) prepared from 125 these animals (Fig 1G) . As judged by eGFP expression, the bi-cistronic Trib1 transgene was 126 expressed in 78.43 ± 2.33% and 65.58 ± 0.92% of blood monocytes and peritoneal macrophages, 127 respectively ( Fig 1G) and overall, the transgene increased BMDM Trib1 RNA levels by 2.49 ± 128 0.43 (SEM) fold (Fig 1G, fourth panel) . Consistent with previous findings (19) the transgene was 129 also expressed in neutrophils, which form a minor component of the immune cell population 130 within very early-stage atherosclerotic lesions (20) . Thus, we detected eGFP in 53.88 ± 2.41% 131 and 34.93 ± 2.96% of Trib1 mTg blood and bone marrow CD11b + /Ly6C -/Ly6G + cells, respectively 132 compared to 25.95 ± 3.16% and 12.42 ± 2.01% in their CD11b + /Ly6C + /Ly6Gmonocyte 133 counterparts ( Fig. S1 E -I) . However, in marked contrast to the reported full-body Trib1 134 knockout mouse (17), Trib1 mKO mice were not afflicted by reduced numbers of total, or 135 individual, white blood cells (Fig. 1H) or by reduced macrophage numbers in their adipose tissue 136 (F4/80 + , Fig. S2A ), liver (F4/80 + , Fig. S2B ) or spleen (F4/80 + and CD206 + , Fig. S2C ). Similar to 137 Trib1 mKO mice, Trib1 mTg mice displayed no gross abnormalities and had WT numbers of white 138 blood cells (Fig. 1H) . Additionally, the sizes of their adipocytes ( Fig. S2A) , liver ( To address the contribution of myeloid Trib1 in early atherosclerosis, we first transplanted bone 142 marrow cells from the Trib1 mKO and Trib1 mTg mice and their respective controls (i.e. non-CRE, 143 floxed KO and Tg alleles) into 12-13 weeks old lethally-irradiated male ApoE -/mice (Fig 2A) . 144 Thus, all recipient mice received ApoE +/+ -bone marrow cells to mitigate the previously described 145 effects of total ablation of this apolipoprotein on both classical/proinflammatory (M1) and 146 alternative/anti-inflammatory (M2) polarization (12) and, to provide them with a physiologically 147 important source of ApoE to aid normalisation of plasma cholesterol levels and of the lipoprotein 148 profile in this otherwise extreme hyperlipidaemic mouse model of human atherosclerosis (12, 21) . 149 Following a seven-week recovery period, the chimeric mice were fed a Western diet containing 150 0.2% cholesterol for 12 weeks. At sacrifice, and consistent with expectations of the study design, 151 the chimeric mice had relatively low plasma cholesterol levels for a mouse model of human 152 atherosclerosis (Fig S3A) . 153 
Results

115
Myeloid-Trib1 Increases Atherosclerosis Burden
154
Unexpectedly, we found less atherosclerosis in the thoracic aorta of Trib1 mKO àApoE -/chimeras 155 than in the control WT mice (Fig. 2B, Fig. S4A ). Conversely, there was a significantly higher 156 atheroma burden in the Trib1 mTg àApoE -/mice ( Fig. 2B, Fig S4A) . Similarly, the lesions in the 157 aortic sinus were on average smaller in the Trib1 mKO àApoE -/mice and larger in the 158 Trib1 mTg àApoE -/mice ( Fig. 2C, Fig. S4B ). However, the collagen contents of the 159 Trib1 mKO àApoE -/and Trib1 mTg àApoE -/in these "early-stage" plaques and their clinical 160 pathology were comparable to those of the chimeric Trib1 mWT àApoE -/mice ( Fig. S4C) . In short, 161 we found that mTrib1 expression increased the atherosclerotic burden of ApoE -/mice, despite 162 having little impact on plasma LDL-cholesterol levels (Fig S3A) . 163 164 To confirm that mTrib1 accelerates the development of atherosclerosis ( Fig. 2B, C) we created an 165 LDL-receptor (Ldlr) knock-down model of human atherosclerosis (22) to induce hyperlipidaemia 166 and atherosclerosis in otherwise WT mice (22) . Specifically, mice were injected with an adeno-167 associated virus (rAAV8) encoding for proprotein convertase subtilisin/kexin 9 ( Fig. 2D) , which 168 previous studies have shown lowers both hepatic and extrahepatic surface cell expression of the 169 Ldlr (23). Following feeding a Western Diet for 12 weeks, this intervention produced comparable, 170 highly significant reductions in LDLR protein levels in the Trib1 mTg and Trib1 mWT mice ( Fig. 2E ) 171 and a similar degree of hyperlipidaemia ( Fig. S3B) . However, despite this and consistent with 172 mTrib1 expression increasing atheroma formation in ApoE -/mice, Trib1 mTg injected with 173 rAAV8-Pcsk9 developed a significantly higher atherosclerotic burden in their aorta and aortic 174 sinus than their similarly injected Trib1 mWT mice ( Fig. 2F-G 177 Next, we investigated the macrophage content and phenotype in the atherosclerotic plaque in each 178 mouse models. This revealed that the aortic sinus lesions of Trib1 mKO àApoE -/mice contained a 179 much smaller MAC3 + immuno-reactive area than the chimeric Trib1 mWT àApoE -/mice, while on 180 average the Trib1 mTg àApoE -/atheromas contained a marginally larger stained area (Fig. 3A, B) . 181 However, there was no preferential loss of YM1 + macrophages in the Trib1 mKO àApoE -/lesions 182 ( Fig. 3B) , consistent with the finding that M2 polarization of Trib1-deficient BMDMs isolated 183 from whole-body Trib1 mKO mice are compromised to a similar extent as M1 polarization (24) . 184 Additionally, we could not attribute the pro-atherogenic activity of myeloid Trib1 expression to a 185 preferential increase in the pro-inflammatory macrophage (NOS2 + ) content of Trib1 mTg àApoE -/-186 plaque ( Fig. 3B, panel 3) . Rather, the increased atherosclerosis in the Trib1 mTg àApoE -/chimeras 187 was attributable to a doubling of foam cell numbers (cells with characteristic foamy appearance 188 and MAC3+ (Fig S4D) ), and on average, these cells were also larger ( Fig. 3A, C, Fig S4D) . 189 Likewise, there was no difference in the sizes of the macrophage populations in the Trib1 mTg -190 Pcsk9 and Trib1 mWT -Pcsk9 mice atheromas ( Fig. 3D) and despite the increased atherosclerotic 191 burden in the transgenic animals ( Fig. 2F, G) , the atherosclerotic lesions of the Pcsk9-Trib1 mTg 192 mice contained larger foam cells ( Fig. 3D) . 193 194 In the Trib1 mTg àApoE -/chimeras, there was a stronger correlation between the mean foam cell 195 size and the percentage of aortic sinus stained by MAC3 than between MAC3 + staining and foam 196 cell numbers ( Fig. 3E ) and, we could not ascribe the observed increase in plaque-foam cell 197 numbers on the effects of mTrib1 expression on blood cholesterol levels (Fig 3E) , or the non-significant rise in LDL-C ( Fig. S3) . In fact, while the Trib1 mWT àApoE -/chimeras with 207 To identify potential cellular mechanisms by which mTrib1 enhances foam cell expansion, we 208 analysed the gene expression characteristics of human TRIB1 High monocytes and TRIB1 High 209 monocyte derived macrophages (MDM) using the microarray RNA data produced in the 210 Cardiogenics Transcriptomic Study (25) . In this dataset, involving samples from 758 individuals, 211 TRIB1 RNA levels were on average higher in monocytes than in MDMs (Fig. 4A , top panel) but, 212 as is evident from the analyses of RNA levels in 596 paired samples, there was no correlation 213 between TRIB1 RNA levels in these two cell types (Fig. 4A, bottom panel) . Moreover, genes 214 differentially expressed in TRIB1 High versus TRIB1 Low monocytes were enriched for different sets 215 of 'DAVID' Gene Ontology cluster terms (Tables S1, S2) than those characterising the more 216 lipid-based transcriptome of TRIB1 High MDM (Fig 4B, C, Tables S3 ).
Myeloid-Trib1 Increases Macrophage/Foam Cell Size in the Atherosclerotic Plaque
Myeloid-TRIB1 Expression Induces OLR1 Expression in Both Mouse and Man.
218
The Cardiogenics Transcriptomic data strongly suggested that the mTRIB1-induced foam cell 219 phenotype stemmed from increased oxLDL uptake rather changes in LDLR and scavenger 220 receptor class B type 1 (which mediates selective HDL-cholesterol uptake and efferocytosis (18)) 221 expression ( Fig 4C) or reductions in ABCG1-and ABCA1-mediated cholesterol efflux (Fig 4B) . 222 Notably, OLR1 was the fourth most differentially expressed gene in the TRIB1 High human MDMs 223 and the most highly altered scavenger receptor in these cells (Fig 4C) . We therefore examined the Table S6 ). Rather HDL-polarised 231 MDMs contained OLR1 and SCARB1 RNA levels indistinguishable from those of non-polarized 232 MDMs (Fig S5A, B , Table S6 ) Finally, to substantiate the evidence for causal TRIB1 233 involvement in OLR1 expression we stained BMDMs for OLR1 protein. OLR1 was detected in 234 twice as many Trib1 mTg cells than their wild-type counterparts ( Fig. 4E) , consistent with the 235 Western Blotting analysis of whole BMDM cell lysates ( Fig. 4F) . To corroborate the evidence for causal mOLR1 involvement in plaque-resident macrophage foam 240 cells expansion, we quantified OLR1 expression in the aortic sinus lesions of our mouse models 241 using an OLR1-antibody that recognizes the cell-surface expressed form of this oxLDL receptor, 242 as well as the proteolytically cleaved (soluble) extracellular form (9). The antibody detected 243 OLR1 in MAC3+ cells and in acellular areas of the mouse aortic sinus lesions, including in 244 regions adjacent to plaque-macrophages ( Fig 5A) . Moreover, as expected from the known 245 expression and regulation of this scavenger receptor in endothelial cells (9), significant amounts 246 of OLR1 was also detected in the non-macrophage (i.e. MAC3-) cell population at the plaque 247 surface of the more hyperlipidemic model of human atherosclerosis (Fig S3, Fig 5A) . Finally, 248 confirming the causal involvement of mTRIB1 in mOLR1 expression ( Fig. 4D-F) , the anti-OLR1 249 antibody detected OLR1 in more of the plaque macrophages of Trib1 mTg àApoE -/mice than in 250 those of the Trib1 mWT àApoE -/control animals (33.89 ± 6.56% vs. 16.18 ± 4.05%); a result 251 which was replicated in the Trib1 mTg -Pcsk9 and Trib1 mWT -Pcsk9 mice (29.35 ± 7.42% vs. 10.38 ± 252 3.36%) (Fig 5A) . Fig. 5D) , consistent with the observation that neither Abca1 nor Abcg1 RNA levels are reduced 264 in these BMDMs (Fig 5D) and, that the Trib1 mTg àApoE -/chimeras have higher, rather than 265 lower, HDL-C levels than their wild-type peers (Fig S3) . Thus, collectively, our results suggest Recent studies have established that oxLDL accumulates steadily in both early-(growing) and 284 mature-(yellow plaque without a necrotic core) stage human coronary plaques but that in more 285 advanced vulnerable plaques (yellow plaques with a necrotic core) this lipoprotein is removed 286 either by metabolism or replacement with other substances, including cell debris (2). This in vivo 287 data dove-tails well with the early in vitro work which showed that while oxLDL promotes 288 macrophage growth and survival in a dose-dependent manner, beyond a certain lipid 289 concentration cell death ensues, albeit by an unknown mechanism (10). Thus, a critical question 290 to consider is whether mTRIB1-induced OLR1 expression serves an (athero-) protective role in 291 the early stage of human atherosclerosis, for example, by reducing the exposure of plaque-292 resident vascular cells (where this disease is initiated) to oxLDL. This lipoprotein is a well-293 described activator of endothelial cell OLR1 expression with the totality of the data indicating 294 that this activation culminates in arterial endothelium dysfunction (9). In the experiments reported 295 here we provide evidence that, mTrib1 transgene expression reduces vascular cell exposure to 296 oxLDL given that it increased the size and lipid contents of plaque-resident foam cells in two 297 independent models of early-stage atherosclerosis by increasing mOLR1 expression and oxLDL 298 uptake. Notably, in the less hyperlipidaemic of these two transgenic models, we also could 299 discern a very strong positive correlation between plaque-macrophage numbers and plasma 300 cholesterol/LDL-C levels, implying that in early-stage atherosclerosis mTrib1 High macrophages 301 (in marked contrast to Trib1-deficient macrophages) are uniquely equipped to increase plaque-302 macrophage numbers in response to lipid excess. 303 304 Based on the strong evidence of a causal link between hyperlipidaemia and CHD (26) and, the 305 demonstration that ablating hepatic TRIB1 expression increased plasma levels of cholesterol, 306 LDL-C and of triglyceride (16), the implication was, which seemed entirely consistent with 307 GWAS results (14, 15) that increasing TRIB1 would be athero-protective. Silencing TRIB1 308 expression in macrophages, however, turns out to be athero-protective, as judged by analyses of 309 the aortas and aortic sinuses from Trib1 mKO àApoE -/chimeric mice, after a 12 weeks Western 310 dietary regime. This counter-intuitive result, which fits well with our in vitro and in vivo analysis 311 of the consequences of mTrib1 High expression on foam cell expansion, suggests moving forward 312 that developing a therapy to specifically silence Trib1 expression in macrophages would provide 313 clinical benefit beyond that of lipid-lowering medications, although full realization of this benefit 314 may require its adoption at an early-stage of atherogenesis. More generally, our study also 315 demonstrates that mechanistic probing of GWAS signals is not only warranted, but critical, to 316 identify both the totality and directionality of disease risk factors, even when, as was the case for 317 TRIB1, the association between a genetic variant(s), disease risk and a major disease-risk factor 318 (plasma lipids) appeared congruent. Hence, we acknowledge that a limitation of the current study 319 is that we have not addressed whether changes in vascular cell TRIB1 expression might affect 320 early-stage atherosclerosis development and, whether the GWAS-CHD signal at the TRIB1 locus 321 reflects that in these cells (and hepatocytes) TRIB1 serves an athero-protective role, in contrast to 322 the situation in plaque-resident macrophages where it induces foam cell expansion. macrophage OLR1 expression via lysophosphatidylcholine stimulation, oxLDL uptake was also 333 induced, prompting them to introduce the concept that macrophages within atheromas may be 334 quiescent with respect to oxLDL uptake until Olr1 expression is induced (28). Here, we validate 335 this concept by demonstrating overexpressing mTrib1-led directly to an increase in OLR1 protein 336 in plaque-resident macrophages, alongside their increased lipid contents and size. Our data also 337 show that by doubling mTrib1 expression, we removed the requirement for an external stimulus 338 to up-regulate OLR1 expression and the consequent clinical sequelae. In fact, the phenotype 339 observed in response to this rise in mTrib1 expression fits well with earlier computational 340 modelling studies that indicated that relatively modest changes in TRIB1 would have a major 341 impact on the activity of MAPK pathways, thus defining the concentration of these proteins is 342 critical for shaping cell function (29). Gene expression studies. 506 RNA from BMDM was prepared as described above. RT-qPCR was performed using primer 507 sequences provided in Table S5 and qPCR were performed, as described above using the primer sets listed in Table S4 .
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Ox-LDL uptake and HDL-mediated cholesterol efflux. 535 Assays were performed on BMDMs cultured for 5 days as described above. OLR1 was detected 536 as described above. For the uptake assays, cells were incubated at 37 0 C for a further 24 h with 
